Sponsor Pipeline

Abramson Cancer Center at Penn Medicine Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
82
Active Trials
46
Recruiting
10
Disease Areas
13
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-12 NCT07199517
Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People…
date change Primary completion pushed: 2030-01 -> 2030-01-31
2026-06-12 NCT07199517
Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People…
date change Completion pushed: 2030-07 -> 2030-07-31
2026-06-11 NCT04332367
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or…
date change Primary completion pushed: 2026-04 -> 2026-09-30
2026-06-11 NCT04332367
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or…
date change Completion pushed: 2026-04 -> 2026-09-30
2026-06-11 NCT05758688
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
date change Primary completion pushed: 2026-05 -> 2026-11
2026-06-11 NCT05758688
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
date change Completion pushed: 2026-11 -> 2026-12
2026-06-02 NCT05852860
A Patient-Oriented Research Mentoring Program in Tobacco Dependence and Implementation…
overall status: "Enrolling By Invitation" → "Active Not Recruiting"
2026-05-27 NCT06089954
Penn Medicine Biobank Return of Results Program
overall status: "Enrolling By Invitation" → "Active Not Recruiting"
2026-05-27 NCT06089954
Penn Medicine Biobank Return of Results Program
date change Primary completion pushed: 2026-04-01 -> 2026-07-01
2026-05-27 NCT06089954
Penn Medicine Biobank Return of Results Program
date change Completion pushed: 2026-08-31 -> 2026-09-30
2026-05-27 NCT04889716
CAR-T Followed by Bispecific Antibodies
Primary endpoint(s) modified
2026-05-27 NCT04889716
CAR-T Followed by Bispecific Antibodies
Enrollment reduced: 42 -> 23 participants
2026-05-27 NCT04523857
ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in…
Enrollment reduced: 66 -> 44 participants
Active Trials by Phase
Phase 2
15
Phase 1/2
2
Phase 1
11
Early Phase 1
3
Not specified
51
Active Trials — top 25 of 82
NCT IDTitleConditionStatus
Phase 2
NCT06591819 Hypofractionated WPPT With HDR Boost Prostate Cancer Recruiting
NCT05496036 Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma Merkel Cell Carcinoma Recruiting
NCT04841148 Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast… Breast Cancer Recruiting
NCT04523857 ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in… Breast Cancer Recruiting
NCT04889716 CAR-T Followed by Bispecific Antibodies Large B-cell Lymphoma Recruiting
NCT06458439 Epcoritamab-CAR T Cells for Large B-cell Lymphomas Lymphoma, Non-Hodgkin Recruiting
NCT04339036 CapTemY90 for Grade 2/3 NET Liver Metastases Neuroendocrine Tumor Grade 2 Recruiting
NCT05916196 [18F]FES PET/.CT in Uterine Cancer Uterine Cancer Recruiting
NCT04332367 Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or… Non-small Cell Lung Cancer Recruiting
NCT05758688 PROton Therapy for Post Surgical Treatment of GYNecologic Cancer Cervical Cancer Recruiting
NCT02153229 Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant… Epitheliod Malignant Pleural Mesothelioma Active, Not Recruiting
NCT04221503 Niraparib/TTFields in GBM Glioblastoma Active, Not Recruiting
NCT05318027 ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy Lung Cancer Active, Not Recruiting
NCT05714657 Shortened Course Adjuvant Radiotherapy Following TORS HPV-Associated Oropharyngeal Squamous Cell Carcinoma Active, Not Recruiting
NCT07059611 Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma Gastric Adenocarcinoma Not Yet Recruiting
Phase 1/2
NCT04691817 Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell… Lung Cancer, Nonsmall Cell Recruiting
NCT04454528 BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy Breast Cancer Active, Not Recruiting
Phase 1
NCT03546829 Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With… Early Stage Non-Small Cell Lung Cancer Recruiting
NCT03863457 [18F] F-GLN by PET/CT in Breast Cancer Breast Cancer Recruiting
NCT07114939 FTT PET/CT in Pancreatic Neuroendocrine Tumors Neuroendocrine Carcinoma Metastatic Recruiting
NCT06413355 FAPI-74 PET/CT in Adults With Fibrosis Fibrosis (Morphologic Abnormality) Recruiting
NCT05488522 SBRT With Atezo/Bev for HCC Hepatocellular Carcinoma Recruiting
NCT02637934 Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer… Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting
NCT06586255 Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer Urothelial Carcinoma Bladder Recruiting
NCT02213497 Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in… Esophageal Cancer Active, Not Recruiting
View all 82 active Abramson Cancer Center at Penn Medicine trials with filters →
Disease Areas
Get alerts when Abramson Cancer Center at Penn Medicine's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free